医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AmpliPhi BioSciences to Host Shareholder Update Conference Call

2014年12月31日 AM09:11
このエントリーをはてなブックマークに追加


 

RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY

AmpliPhi BioSciences Corporation (OTCQB:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a shareholder update conference call on Monday, January 05, 2015 at 4:15 PM ET.

AmpliPhi’s Chairman, Jeremy Curnock Cook, will lead the call which will provide current and prospective investors highlights of the Company’s accomplishments during 2014 and provide an overview of corporate initiatives for the year moving forward.

Participants can access the call by dialing 1-888-576-4387 (United States) or 1-719-325-2361 (International). The conference code is 2606006. The conference call will also be available via a live webcast on the investor relations section of AmpliPhi’s website at www.ampliphibio.com. Access the website 15 minutes prior to the call to download and install any necessary audio software. An archived webcast reply will be available on the Company’s website for 60 days.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (OTCQB:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE:XON), the U.S. Army, The Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The Company is headquartered in Richmond, Virginia with additional manufacturing and research operations in Ljubljana, Slovenia and Sydney, Australia. For more information, visit www.ampliphibio.com.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release about the potential use of bacteriophages to treat bacterial infections, the development of bacteriophage-based therapies and AmpliPhi’s clinical, research and development plans are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi’s business in general, see AmpliPhi’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as amended, filed with the Securities and Exchange Commission (SEC) on September 12, 2014.

CONTACT

At the Company:
Baxter Phillips III
Chief Business
Officer
+1-804-754-5442
bfp@ampliphibio.com
or
US
Media Enquiries:

Lazar Partners
Fern Lazar/Danielle
Lewis
+1-212-867-1762
ampliphi@lazarpartners.com
or
ROW
Media Enquiries:

Instinctif Partners
Sue
Charles/Gemma Howe/
Daniel Gooch/Emma Barlow
UK: +44 (0)20
7457 2020
AUS: +61 (0)466 924218
ampliphi@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent